Your World of Legal Intelligence
 United Kingdom | +44 (0) 20 7284 8080

Photocure reports positive results for Hexvix Phase III trial in China.

Document Cited in Related
Vincent

NORDIC BUSINESS REPORT-October 12, 2023-Photocure reports positive results for Hexvix Phase III trial in China

(C)2023 M2 COMMUNICATIONS http://www.m2.co.uk

Photocure ASA (OSE:PHO), a provider of solutions to improve the lives of bladder cancer patients, said on Thursday that its partner Asieris Pharmaceuticals (SSE:688176) has reported the results of the Hexvix (APL-1706) Phase III clinical trial in China during a presentation at the 43rd Congress of the Société Internationale d'Urologie (SIU).

The study reveals that, within the Chinese population, Hexvix blue light cystoscopy (BLC) surpassed white light cystoscopy (WLC) in the detection of bladder cancer, especially carcinoma in situ (CIS), and demonstrated favourable tolerability.

These results, deemed highly statistically significant, align with Photocure's own randomized controlled trials (RCTs), emphasizing the clinical advantages of Hexvix BLC over WLC, including superior tumour detection and a well-tolerated profile with no severe adverse events. Asieris's Phase III Hexvix trial represents the first RCT performed with high-definition 4K blue light equipment.

This prospective...

To continue reading

Request your trial
COPYRIGHT Normans Media Ltd.

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT